The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

The Phase 1b/2 SCLC trial and Phase 2 VIRO-25 trial are actively enrolling in dose escalation cohorts with an aim to optimize efficacy, safety, and tolerability of Olvi-Vec. The trials are being ...

Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung cancers are non-small cell lung cancers, in which tumor cells are larger and ...

Researchers at the Francis Crick Institute and AlveoliX have developed the first human 'lung-on-chip' model using stem cells ...

Rare inherited genetic variants significantly increase familial lung cancer risk, offering new targets for early detection.

Researchers at the Francis Crick Institute and AlveoliX have developed the first human lung-on-chip model using stem cells ...

Most people associate lung cancer primarily with smoking, but growing evidence suggests diet plays a more significant role than previously thought. While numerous foods help protect against cancer, ...

Lung cancer has been widely perceived as a disease that predominantly affects men. However, recent epidemiological data indicate that it is increasingly being diagnosed in women. In fact, a large ...

Lung cancer continues to have a profound impact on many communities, but the disparity is especially notable within Black populations. In these communities, lung cancer incidence and mortality rates ...